Quantifying the health benefits of genetic tests: The importance of a population perspective

Genetics in Medicine

Volumn 8, Issue 3, 2006, Pages 191-195

  Khoury, Muin J ^a   Jones, Kari ^b   Grosse, Scott D ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b National Center for Health Marketing   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY DIAGNOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MORBIDITY; MORTALITY; NEWBORN SCREENING; NOTE; PHENYLKETONURIA; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SMOKING CESSATION; SYMPTOMATOLOGY; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH SURVEY; METHODOLOGY; PUBLIC HEALTH; REVIEW; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; POPULATION SURVEILLANCE; PUBLIC HEALTH; RISK FACTORS;

EID: 33645798616     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000206278.37405.25     Document Type: Note

References (27)

1. Bell J. Predicting disease using genomics. Nature 2004;429:453-456.
2. Davis R, Khoury MJ. The journey to personalized medicine. Personalized Med 2005;2:1-4.
3. Khoury MJ. Genetics and Genomics in Practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003;5:261-268.
4. Haga SB, Khoury MJ, Burke W. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet 2003;34:347-350.
5. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev 2004;3:739-748.
6. Vineis P, Christiani DC. Genetic testing for sale. Epidemiology 2004;15:3-5.
7. Wilson JMG, Jungner F. Principles and practice of screening for disease (Public Health Papers No. 34). Geneva: World Health Organization, 1968.
8. Goel V. Appraising organised screening programmes for testing for genetic susceptibility to cancer. BMJ 2001;322:1174-1178.
9. Khoury MJ, McCabe L, McCabe ERL. Population screening in the age of genomic medicine. N Engl J Med 2003b;348:50-58.
10. Khoury MJ, Yang Q, Gwinn M, Little J, Flanders WD. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med 2004;6:38-47.
11. Maciosek MV, Coffield AB, McGinnis JM, et al. Methods for priority setting among clinical preventive services. Am J Prev Med 2001;21:10-19.
12. Wacholder S. The impact of a prevention effort on the community. Epidemiology 2005;16:1-3.
13. Ryan S, Scriver CR. Phenylalanine hydroxylase deficiency. GeneReview 2004. Accessed on June, 2005 at: http://www.geneclinics.org/servlet/access?id= 8888891& key=yyiovlqq62IK4Xh4y&gry=INSERTGRY&fcn=y&fw= r8lR&filename=/glossary/ profiles/pku/details.html.
14. American Academy of Pediatrics. Committee on Genetics. Newborn screening fact sheets. Pediatrics. 1996;98:473-501.
15. Jelliffe-Pawlowski LL, Shaw GM, Nelson V, Harris JA. Risk of mental retardation among children born with birth defects. Arch Pediatr Adolesc Med 2003;157:545-550.
16. Austin MA, Zimmern RL, Humphries SE. High "population attributable fraction" for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genet Med 2002;4:275-278.
17. Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Int Med 2001;161:242-247.
18. CDC National Center for Health Statistics, National Vital Statistics Report, vol. 52, no. 3, Accessed June, 2005 at: http://www.cdc.gov/nchs.
19. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38.
20. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565.
21. Collins FS. Medical and Societal Consequences of the Human Genome Project. N Engl J Med 1999;341:28-37.
22. Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003;4:231-239.
23. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2:E29.
24. Scheuner MT, Wang SJ, Raffel LJ, Larabell SK, Rotter JI. Family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood. Am J Med Genet 1997;71:315-324.
25. Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, et al. Can family history be used as a tool for public health and preventive medicine? Genet Med 2002;4:304-310.
26. Department of Health and Human Services. U.S. Surgeon General's Family History Initiative surgeon general family history initiative. Accessed on June, 2005 at: http:// www.hhs.gov/familyhistory/.
27. CDC family history public health initiative. Accessed on June, 2005 at: http://www. cdc.gov/genomics/activities/famhx.htm.